EX-31.1 - Grapefruit USA, Inc ex31-1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 Commission file number 000-50099...
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ As of December 31, 2016, the aggregate market value of the voting stock held by non-affiliates of the registrant was $128,400. For purposes of this information, ...
(發布日期2010.6.18) 29 Trichloroethylene 三氯乙烯 30 Boric acid 硼酸 Chemical cleaning and industrial Skimmed 化Gla學ss清, e洗nam,e工l, m業ed脫ic脂ine, metallurgy 玻璃,搪瓷,醫藥,冶金 31 Disodium tetraborate, anhydrous 四硼酸鈉,無水 Analytical reagent 分析試劑 32 Tetraboron disodium heptaoxide...
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ As of December 31, 2017, the aggregate market value of the voting stock held by non-affiliates of the registrant was $195,900. For purposes of this information, ...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2012 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...
With no real commercial formulations, it is worthwhile to discuss the major concerns that are stalling complex emulsions from seeing the light of the day, not only in pharmaceuticals but also in other commercial applications such as cosmetics and in the food industry. Below, we discuss the possib...
and Materials Degradation (CMD)CosmeticsCOVIDCraniomaxillofacial Trauma & Reconstruction (CMTR)CropsCryoCryptographyCrystalsCurrent Issues in Molecular Biology (CIMB)Current OncologyDairyDataDentistry JournalDermatoDermatopathologyDesignsDiabetologyDiagnosticsDieteticsDigitalDisabilitiesDiseasesDiversityDNADronesDrugs and ...